A RUDN University chemist created anti-tumour compounds that are up to 80 times more effective than their counterparts

A RUDN University chemist created anti-tumour compounds that are up to 80 times more effective than their counterparts

A chemist from RUDN University has created platinum complex compounds that are superior in activity to cisplatin, the drug for the treatment of tumour diseases. The new compounds turned out to be also less toxic to healthy cells.

Platinum-based anticancer drugs — cisplatin, oxaliplatin, and carboplatin — are used for chemotherapy in about half of cancer cases. They penetrate cells and interact with DNA molecules. The process is fatal for rapidly dividing cancer cells because the drugs prevent the duplication of DNA molecules, which is necessary for successful division. Since cancer cells divide rapidly, they are the first to be affected. Still, platinum derivatives have certain disadvantages: low stability under physiological conditions and high toxicity.

To create new drugs, a strategy that involves the development of hybrid molecules is often used in modern chemistry. Such substances consist of two or more active fragments that are linked by a linker into one molecule. They usually have a double action, characteristic of each of the fragments.

A chemist from RUDN University, candidate of biological sciences Kirill Kirsanov, created a series of new drugs: hybrids of cisplatin, lonidamine, and bexarotene. Lonidamine itself has an anti-tumour effect due to its ability to suppress energy metabolism in cancer cells. In combination with radiation therapy, it is used to treat brain tumours. Bexarotene is used for the treatment of lung cancer and breast cancer, as it inhibits the growth of tumour cells of hematopoietic and squamous origin.

A derivative of cisplatin with bexarotene turned out to be the most promising. A combination of succinic acid and ethylenediamine was used as a linker. In tests conducted on four tumour cell lines, the hybrid drug was 80 times more active than bexaroten and 20 times higher on average than cisplatin, and the new drug was 80 times more active than cisplatin on MCF7D cell line. Based on the resulting leading compound, new and more effective anti-tumour medications can be developed.

The paper was published in the journal Inorganica Chimica Acta.

All news
15 Jun
Heavy Metals Make Soil Enzymes 3 Times Weaker, Says a Soil Scientist from RUDN University

Heavy metals suppress enzyme activity in the soil by 3-3.5 times and have especially prominent effect on the enzymes that support carbon and sulfur circulation. This was discovered by a soil scientist from RUDN together with his colleagues from Chile, Germany, the UK and Venezuela. The data obtained by the team can lead to more efficient use and fertilization of agricultural lands.

09 Jun
Multilingual Education during COVID-19: University Teachers from Several Continents and 18 Countries Explored Common and Specific Features of Remote Training

The RUDN University Academic Council Commission on Foreign Languages held its June research seminar in cooperation with international community of language teachers who became part of the international pro-bono project on challenges and solutions to foreign languages training during COVID-19.

07 Jun
RUDN University Biologists Studied the Effect of Jungles on Global Warming

Biologists from RUDN University described the role of tropical rainforests in the production of methane, the second most harmful greenhouse gas after CO2. It turned out that some areas of rainforests not only consumed methane but also emitted it.